We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Outline
- Latest data of women living with obesity
- Trend in obesity and severe obesity among adults
- Obesity results from the interaction between the modern environment and our biology
- BMI does not reflect the complexity of obesity
- Genetic factors regulate body weight
- Genetics of fat distribution is largely separate from that of BMI
- Measures of adiposity and fat distribution that can be used to assess risk in obesity
- Obesity is a risk factor for many other diseases
- BMI and all-cause mortality
- Summary and conclusions (part 1)
- What should we do about obesity?
- Strategies for obesity prevention
- Public health interventions: Diet
- Public health vs. interventions for individuals? We need both
- Goals and benefits of effective obesity management
- How much weight loss is needed to improve obesity-related complications?
- Lifestyle weight management: Three core components
- Lifestyle weight management: Dietary change — energy restriction
- Lifestyle weight management: Physical activity
- Lifestyle weight management: Behavioural change and psychological support
- Maintenance of weight loss is difficult for people who have successfully lost weight
- Summary: Effects of energy restriction (‘dieting’)
- Bariatric surgery procedures manipulate metabolic and hormonal systems
- Long-term benefits of weight loss after bariatric surgery
- Obesity treatment: Bridging the gap between lifestyle interventions and surgery
- Approved drug treatments for weight management
- GLP-1: A gut peptide for treatment of diabetes and obesity
- Semaglutide
- Weight loss with semaglutide 2.4 mg once weekly in STEP trials (overweight / obesity)
- Semaglutide 2.4 mg for obesity: Weight change over time (STEP 1 vs. STEP 5)
- Semaglutide: STEP 1 observational extension
- Semaglutide — STEP 1: Prevalence of metabolic syndrome
- SELECT clinical trial: Semaglutide in high CVD risk obesity without diabetes
- Cumulative incidence of MACE SELECT: Primary cardiovascular composite endpoint
- Safety summary with semaglutide 2.4 mg in people with obesity
- Tirzepatide
- Percentage change in body weight: SURMOUNT clinical trial program
- SURMOUNT 1: Obesity outcomes in people with prediabetes after 176 weeks treatment
- SURMOUNT 4: Long-term weight loss with tirzepatide
- Tirzepatide in obesity: Adverse events summary
- GLP-1 agonism plus GLP-1 antibody: Phase 1 results
- MariTide: Robust weight loss in people living with overweight or obesity — phase 2 study
- Triple agonist retadrutide: GLP-1, GIP, glucagon
- New oral options look promising
- Pharmacotherapy combined with lifestyle intervention can provide 17–24% weight loss
- Summary and conclusions
- Thank you
Topics Covered
- Trends in obesity
- Strategies for obesity prevention
- Interventions for treatment of obesity
- Approved drugs for obesity treatment
- Obesity management
- Clinical trials
Links
Series:
Categories:
Therapeutic Areas:
External Links
- Slide 6: Obesity system map
- Slide 7: WHO ICD-11
- Slide 20, 21, 23, 28: Overweight and obesity management
- Slide 36, 37: Semaglutide 2.4mg reduces the risk of adverse cardiovascular events by 20%
- Slide 38: EMA- Wegovy
- Slide 43: EMA- Mounjaro
- Slide 45: Amgen announces robust weight loss with MariTide in people living with obesity or overweight at 52 weeks in a phase 2 study
Talk Citation
Wilding, J. (2026, October 29). New standards in weight management [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 29, 2026, from https://doi.org/10.69645/RJTD2476.Export Citation (RIS)
Publication History
- Published on October 29, 2026
Financial Disclosures
- Prof. John Wilding, Consulting fees (no personal payment): Alnylam, Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki, Kailera, Lilly, Menarini, Metsera, Novo Nordisk, Pfizer, Regeneron, Response Pharmaceuticals, Rhythm Pharmaceuticals, Roche, Shionogi Research contracts (no personal payment): Amgen, Novo Nordisk, Lilly, Rhythm Pharmaceuticals Clinical trial steering committee/DSMB: Amgen, AstraZeneca, Lilly, Novo Nordisk, NIHR Lecture Fees: Abbvie, AstraZeneca, Boehringer Ingelheim, Lilly, Menarini, Novo Nordisk.
A selection of talks on Cardiovascular & Metabolic
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is John Wilding.
I'm a professor of medicine
at the University
of Liverpool and
a consultant physician at
Aintree University
Hospital in Liverpool,
where I spend some of
my time looking after
people with obesity
and type 2 diabetes.
I'm going to talk today about
new standards in
weight management.
0:20
These are my disclosures.
0:25
So I will start with an outline.
At the beginning, I'm
going to set the scene
and discuss how
common obesity is
and why it matters to
healthcare professionals
and society as a whole.
We'll have a brief consideration
of why there is an
epidemic of obesity
and how obesity leads
to its complications
to other diseases.
Then we'll discuss what
we can do about obesity,
both prevention at
a societal level
and treatment at an
individual level.
0:58
If we look at global data,
and here we have data from
the World Obesity
Federation focusing on
women living with obesity
around the world.
We can see that there are
quite large areas of the world
where more than 30%
of the population
are living with obesity
and many other areas
where the prevalence
is above 20%.
There are really very
few parts of the world
where obesity is rare.
These data are, of
course, for women,
but we're seeing
the same in men,
and we're also seeing
increasing rates
of obesity in young
people and children.
1:36
Here we see some data
from the United Kingdom
from the Health Survey
for England up to 2022.
You can see here that
nearly 30% of the UK population
are living with obesity,
and nearly 2 million
have severe obesity
as classified here as a
body mass index above 40.
These people would be
eligible for treatment within
specialist services or perhaps
to have bariatric surgery.
This has become such a problem
over the last 20-30 years,
as you can see
from these slides.
Why is this happening?
Well, we know from this work